Attention-Deficit/Hyperactivity Disorder Clinical Trial
Official title:
Effectiveness of Social Virtual Reality Based Intervention on Enhancing Social Interaction Skills in Children With Attention-deficit/Hyperactivity Disorder: a Pilot Randomised Controlled Trial
The study targets children with diagnosed ADHD and aims to (1) develop a social virtual reality based (SocVR) intervention and (2) investigate its effects on improving the social skills and executive functioning of inhibitions, emotional control and attention of the children compared to traditional social skills training. The study will be a three-arm parallel randomised controlled trial comparing the effects of a SocVR with traditional social skills training on social skills and executive functioning of children with ADHD. The study period is 2 months, including 4 weeks (2 sessions per week) of intervention and control, followed by a 4-week follow-up. The participants will be assessed at three time points (i.e. at baseline, 4 weeks and 4 weeks follow-up). The guidelines of Whitehead et al. (2016) suggested that recommended that at least 16 subjects per group for medium effect size in pilot RCT and 15% attrition over time can be expected. Thus, the minimum sample size per group was 20. A total of 60 participants will be recruited in which 20 participants in the social VR group, 20 in the traditional social skills group and 20 in the waitlist control group.
Status | Not yet recruiting |
Enrollment | 60 |
Est. completion date | March 31, 2023 |
Est. primary completion date | February 28, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 6 Years to 12 Years |
Eligibility | Inclusion Criteria: - Aged between 6 and 12 years - Ethnic Chinese - Residing in Hong Kong - Having received a diagnosis of ADHD by Child Assessment Service in Hong Kong or via private practice - Stable on pharmacological and/or psychological treatment for ADHD 8 weeks before baseline (determined by health care professionals on the basis of medication data and behavioural observation) - No initiation or change of pharmacological treatment for ADHD during the intervention period ability to read Chinese, and speak and listen to Cantonese by the child and by at least one of their parents or legal guardian - Willing to provide informed consent by both participants and one of their parents or legal guardian Exclusion Criteria: - Comorbid autism - Mental retardation - An estimated IQ lower than 85 (using the Wechsler Intelligence Scale for Children - Fourth Edition (Hong Kong) (WISC-IV(HK))) - Autism spectrum disorder (previously diagnosed by health care professionals) - Comorbid acute psychiatric disorder (previously diagnosed by health care professionals) - With a severe physical disability (e.g., blindness, deafness) or learning disability (e.g., dyslexia). |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
The Hong Kong Polytechnic University |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Simulator Sickness Questionnaire | This questionnaire measures the motion sickness or physical discomfort of the participants in the VR environment. Nine items will be measured, including general discomfort, fatigue, headache, eyestrain, sweating, nausea, difficulty concentrating, blurred vision and dizziness. Yes or no questions were used for each item. | Week 4 post-interventioin | |
Primary | Social Skills Rating Scale | This scale consists of 3 subscales, including self-control, assertiveness and initiative, and cooperation, with a total of 31 items. A 3-point Likert scale (never, sometimes, often) is used to score. | Baseline | |
Primary | Social Skills Rating Scale | This scale consists of 3 subscales, including self-control, assertiveness and initiative, and cooperation, with a total of 31 items. A 3-point Likert scale (never, sometimes, often) is used to score. | Change from baseline social skills at week 4 post-interventioin | |
Primary | Social Skills Rating Scale | This scale consists of 3 subscales, including self-control, assertiveness and initiative, and cooperation, with a total of 31 items. A 3-point Likert scale (never, sometimes, often) is used to score. | Week 8 follow-up | |
Secondary | Behavior Rating Inventory of Executive Function | This scale is used to assess the executive functioning of children which will be scored by the participants' parents. The subscales of inhibitions (16-item), emotional control (10-item) and shifting (10-item) will be adopted in this study. A 3-point Likert scale (never, sometimes, often) is used to score. | Baseline | |
Secondary | Behavior Rating Inventory of Executive Function | This scale is used to assess the executive functioning of children which will be scored by the participants' parents. The subscales of inhibitions (16-item), emotional control (10-item) and shifting (10-item) will be adopted in this study. A 3-point Likert scale (never, sometimes, often) is used to score. | Change from baseline social skills at week 4 post-interventioin | |
Secondary | Behavior Rating Inventory of Executive Function | This scale is used to assess the executive functioning of children which will be scored by the participants' parents. The subscales of inhibitions (16-item), emotional control (10-item) and shifting (10-item) will be adopted in this study. A 3-point Likert scale (never, sometimes, often) is used to score. | Week 8 follow-up |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02251743 -
Double-Blind 2-Site Randomized Clinical Trial of Neurofeedback for ADHD
|
N/A | |
Completed |
NCT02226445 -
Treatment Drop-out and Missed Appointments Among Adults With ADHD
|
N/A | |
Completed |
NCT01342445 -
Effects of LDX on Functioning of College Students With ADHD
|
Phase 4 | |
Not yet recruiting |
NCT00391495 -
Inflammation in Children With Attention-Deficit/Hyperactivity Disorder
|
N/A | |
Completed |
NCT00528697 -
A Safety and Efficacy Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)
|
Phase 2 | |
Completed |
NCT00494819 -
Validity of ADHD Subtypes Using Neuropsychological Measure
|
N/A | |
Completed |
NCT02217371 -
Role of Circadian and Homeostatic Systems in the Regulation of Wakefulness in Adult Patients With Attention Deficit Disorder With or Without Hyperactivity
|
N/A | |
Completed |
NCT01081132 -
Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl
|
Phase 3 | |
Completed |
NCT06064942 -
Multiple Family Narrative Therapy for Chinese Families of Children With Attention Deficit Hyperactivity Disorder
|
N/A | |
Completed |
NCT00391729 -
A Dose-Ranging, Cross-over Study of the Safety and Efficacy of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
|
Phase 2 | |
Completed |
NCT00191048 -
Treatment With Atomoxetine Hydrochloride in Children and Adolescents With ADHD
|
Phase 4 | |
Terminated |
NCT00554385 -
A Safety and Tolerability Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)
|
Phase 2 | |
Completed |
NCT00997984 -
Tolerability and Efficacy of AM and PM Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Children 6-12 With Attention-Deficit/Hyperactivity Disorder (ADHD) (The ADHD Tempo Study)
|
Phase 3 | |
Completed |
NCT02096952 -
Methylphenidate ER Liquid Formulation in Adults With ASD and ADHD
|
Phase 4 | |
Recruiting |
NCT02623114 -
Attention-deficit/Hyperactivity Disorder Translational Center for Identifying Biomarkers
|
Phase 4 | |
Completed |
NCT01351246 -
Guided Self-Help for Parents of Children With Attention-Deficit/Hyperactivity Disorder (ADHD)
|
N/A | |
Completed |
NCT00686933 -
Long Term Safety and Tolerability Study of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
|
Phase 2 | |
Completed |
NCT00491647 -
Time Perception Deficits and Attention-Deficit/Hyperactivity Disorder
|
N/A | |
Completed |
NCT01081145 -
Maintenance of Efficacy of Extended-Release Guanfacine HCl in Children and Adolescents With Attention-deficit/Hyperactivity Disorder (ADHD)
|
Phase 3 | |
Recruiting |
NCT06185985 -
Open-label Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD and Mood Symptoms
|
Phase 4 |